Acute Myeloid Leukemia (AML)

Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab

Original Publication Date

June 21, 2025

Article Source

External Web Content

Abstract Background: RNA splicing factor (SF) mutations are associated with adverse outcomes in patients with acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes/neoplasms (HR-MDS). Preclinical data suggest that aberrant RNA splicing can lead to the generation…

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD–mutated AML

Original Publication Date

May 8, 2025

Article Source

External Web Content

Abstract BMT CTN (Blood and Marrow Transplant Clinical Trials Network) 1506 (“MORPHO”) was a randomized study of gilteritinib compared with placebo as maintenance therapy after hematopoietic cell transplantation (HCT) for patients with FLT3-ITD–mutated acute myeloid leukemia (AML…

Jesus Gonzalez Lugo, MD

Institution

The University of Kansas

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Aplastic Anemia

Myelodysplastic Syndromes (MDS)

Myeloproliferative Neoplasms (MPN)

Read more about Jesus Gonzalez Lugo, MD

Praneeth Baratam, MBBS

Institution

Medical University of South Carolina

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Aplastic Anemia

Myelodysplastic Syndromes (MDS)

Myeloproliferative Neoplasms (MPN)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Read more about Praneeth Baratam, MBBS

Kris Michael Mahadeo, MD MPH

Institution

Duke University Medical Center

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Aplastic Anemia

Myelodysplastic Syndromes (MDS)

Pediatric

Read more about Kris Michael Mahadeo, MD MPH

David Swoboda,MD

Institution

Tampa General Hospital Cancer Institute

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Aplastic Anemia

Myelodysplastic Syndromes (MDS)

Myeloproliferative Neoplasms (MPN)

Read more about David Swoboda,MD

Jen Chin Wang, MD

Institution

New York Cancer & Blood Specialists

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Read more about Jen Chin Wang, MD

Ronan Swords, MD, PhD, FRCPI, FRCPath

Institution

OHSU Knight Cancer Institute

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes (MDS)

Read more about Ronan Swords, MD, PhD, FRCPI, FRCPath

Stephen A. Strickland, MD, MSCI

Institution

Sarah Cannon Transplant & Cellular Therapy Network

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes (MDS)

Myeloproliferative Neoplasms (MPN)

Read more about Stephen A. Strickland, MD, MSCI

Brady L. Stein, MD

Institution

Northwestern University Feinberg School of Medicine

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes (MDS)

Myeloproliferative Neoplasms (MPN)

Read more about Brady L. Stein, MD

Subscribe to Acute Myeloid Leukemia (AML)

AAMDSIF Awareness Week

Acute Myeloid Leukemia (AML)

Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD–mutated AML

Jesus Gonzalez Lugo, MD

Praneeth Baratam, MBBS

Kris Michael Mahadeo, MD MPH

David Swoboda,MD

Jen Chin Wang, MD

Ronan Swords, MD, PhD, FRCPI, FRCPath

Stephen A. Strickland, MD, MSCI

Brady L. Stein, MD

Website Feedback